Search Results - "Tutt, Andrew"

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors by Lord, Christopher J, Tutt, Andrew N.J, Ashworth, Alan

“…The genetic concept of synthetic lethality, in which the combination or synthesis of mutations in multiple genes results in cell death, provides a framework to…”
Get full text

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers by Watkins, Johnathan A, Irshad, Sheeba, Grigoriadis, Anita, Tutt, Andrew N J

“…Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious…”
Get full text

Molecular alterations in triple-negative breast cancer—the road to new treatment strategies by Denkert, Carsten, Dr, Liedtke, Cornelia, MD, Tutt, Andrew, MD, von Minckwitz, Gunter, MD

“…Summary Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional…”
Get full text

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer by Chabanon, Roman M, Muirhead, Gareth, Krastev, Dragomir B, Adam, Julien, Morel, Daphné, Garrido, Marlène, Lamb, Andrew, Hénon, Clémence, Dorvault, Nicolas, Rouanne, Mathieu, Marlow, Rebecca, Bajrami, Ilirjana, Cardeñosa, Marta Llorca, Konde, Asha, Besse, Benjamin, Ashworth, Alan, Pettitt, Stephen J, Haider, Syed, Marabelle, Aurélien, Tutt, Andrew Nj, Soria, Jean-Charles, Lord, Christopher J, Postel-Vinay, Sophie

“…The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase…”
Get full text

The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin by Krastev, Dragomir B., Li, Shudong, Sun, Yilun, Wicks, Andrew J., Hoslett, Gwendoline, Weekes, Daniel, Badder, Luned M., Knight, Eleanor G., Marlow, Rebecca, Pardo, Mercedes Calvo, Yu, Lu, Talele, Tanaji T., Bartek, Jiri, Choudhary, Jyoti S., Pommier, Yves, Pettitt, Stephen J., Tutt, Andrew N. J., Ramadan, Kristijan, Lord, Christopher J.

“…Poly (ADP-ribose) polymerase (PARP) inhibitors elicit antitumour activity in homologous recombination-defective cancers by trapping PARP1 in a chromatin-bound…”
Get full text

RORγt + Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers by Irshad, Sheeba, Flores-Borja, Fabian, Lawler, Katherine, Monypenny, James, Evans, Rachel, Male, Victoria, Gordon, Peter, Cheung, Anthony, Gazinska, Patrycja, Noor, Farzana, Wong, Felix, Grigoriadis, Anita, Fruhwirth, Gilbert O, Barber, Paul R, Woodman, Natalie, Patel, Dominic, Rodriguez-Justo, Manuel, Owen, Julie, Martin, Stewart G, Pinder, Sarah E, Gillett, Cheryl E, Poland, Simon P, Ameer-Beg, Simon, McCaughan, Frank, Carlin, Leo M, Hasan, Uzma, Withers, David R, Lane, Peter, Vojnovic, Borivoj, Quezada, Sergio A, Ellis, Paul, Tutt, Andrew N J, Ng, Tony

“…Cancer cells tend to metastasize first to tumor-draining lymph nodes, but the mechanisms mediating cancer cell invasion into the lymphatic vasculature remain…”
Get full text

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer by Tutt, Andrew N.J, Garber, Judy E, Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D, de Azambuja, Evandro, Fielding, Anitra, Balmaña, Judith, Domchek, Susan M, Gelmon, Karen A, Hollingsworth, Simon J, Korde, Larissa A, Linderholm, Barbro, Bandos, Hanna, Senkus, Elżbieta, Suga, Jennifer M, Shao, Zhimin, Pippas, Andrew W, Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A, Lucas, Peter C, Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G, Costantino, Joseph P, Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R, Yothers, Greg, Campbell, Christine, Geyer, Charles E

“…Among patients who had mutations in BRCA1 or BRCA2 and were at high risk for disease progression, those who were assigned to a year of olaparib adjuvant…”
Get full text

Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype by Fitzpatrick, Amanda, Iravani, Marjan, Mills, Adam, Vicente, David, Alaguthurai, Thanussuyah, Roxanis, Ioannis, Turner, Nicholas C., Haider, Syed, Tutt, Andrew N. J., Isacke, Clare M.

“…Breast cancer leptomeningeal metastasis (BCLM), where tumour cells grow along the lining of the brain and spinal cord, is a devastating development for…”
Get full text

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy by Smith, Graeme C. M, Ashworth, Alan, Farmer, Hannah, McCabe, Nuala, Lord, Christopher J, Tutt, Andrew N. J, Johnson, Damian A, Richardson, Tobias B, Santarosa, Manuela, Dillon, Krystyna J, Hickson, Ian, Knights, Charlotte, Martin, Niall M. B, Jackson, Stephen P

“…BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other…”
Get full text

Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance by Pettitt, Stephen J, Frankum, Jessica R, Punta, Marco, Lise, Stefano, Alexander, John, Chen, Yi, Yap, Timothy A, Haider, Syed, Tutt, Andrew N J, Lord, Christopher J

“…Reversion mutations in or are associated with resistance to PARP inhibitors and platinum. To better understand the nature of these mutations, we collated,…”
Get more information

Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B by Akre, Monica K, Starrett, Gabriel J, Quist, Jelmar S, Temiz, Nuri A, Carpenter, Michael A, Tutt, Andrew N J, Grigoriadis, Anita, Harris, Reuben S

“…Molecular, cellular, and clinical studies have combined to demonstrate a contribution from the DNA cytosine deaminase APOBEC3B (A3B) to the overall mutation…”
Get full text

Signatures of mutational processes in human cancer by Alexandrov, Ludmil B., Nik-Zainal, Serena, Wedge, David C., Aparicio, Samuel A. J. R., Behjati, Sam, Biankin, Andrew V., Bignell, Graham R., Bolli, Niccolò, Borg, Ake, Børresen-Dale, Anne-Lise, Boyault, Sandrine, Burkhardt, Birgit, Butler, Adam P., Caldas, Carlos, Davies, Helen R., Desmedt, Christine, Eils, Roland, Eyfjörd, Jórunn Erla, Foekens, John A., Greaves, Mel, Hosoda, Fumie, Hutter, Barbara, Ilicic, Tomislav, Imbeaud, Sandrine, Imielinski, Marcin, Jäger, Natalie, Jones, David T. W., Jones, David, Knappskog, Stian, Kool, Marcel, Lakhani, Sunil R., López-Otín, Carlos, Martin, Sancha, Munshi, Nikhil C., Nakamura, Hiromi, Northcott, Paul A., Pajic, Marina, Papaemmanuil, Elli, Paradiso, Angelo, Pearson, John V., Puente, Xose S., Raine, Keiran, Ramakrishna, Manasa, Richardson, Andrea L., Richter, Julia, Rosenstiel, Philip, Schlesner, Matthias, Schumacher, Ton N., Span, Paul N., Teague, Jon W., Totoki, Yasushi, Tutt, Andrew N. J., Valdés-Mas, Rafael, van Buuren, Marit M., van ’t Veer, Laura, Vincent-Salomon, Anne, Waddell, Nicola, Yates, Lucy R., Zucman-Rossi, Jessica, Andrew Futreal, P., McDermott, Ultan, Lichter, Peter, Meyerson, Matthew, Grimmond, Sean M., Siebert, Reiner, Campo, Elías, Shibata, Tatsuhiro, Pfister, Stefan M., Campbell, Peter J., Stratton, Michael R.

“…All cancers are caused by somatic mutations; however, understanding of the biological processes generating these mutations is limited. The catalogue of somatic…”
Get full text

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer by Loi, Sherene, Haibe-Kains, Benjamin, Majjaj, Samira, Lallemand, Francoise, Durbecq, Virginie, Larsimont, Denis, Gonzalez-Angulo, Ana M., Pusztai, Lajos, Symmans, W. Fraser, Bardelli, Alberto, Ellis, Paul, Tutt, Andrew N. J., Gillett, Cheryl E., Hennessy, Bryan T., Mills, Gordon B., Phillips, Wayne A., Piccart, Martine J., Speed, Terence P., McArthur, Grant A., Sotiriou, Christos, Brugge, Joan S.

“…PIK3CA mutations are reported to be present in approximately 25% of breast cancer (BC), particularly the estrogen receptor—positive (ER+) and…”
Get full text

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? by Turner, Nicholas C, Tutt, Andrew N J

“…A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin…”
Get full text

Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis by Fitzpatrick, Amanda, Iravani, Marjan, Mills, Adam, Childs, Lucy, Alaguthurai, Thanussuyah, Clifford, Angela, Garcia-Murillas, Isaac, Van Laere, Steven, Dirix, Luc, Harries, Mark, Okines, Alicia, Turner, Nicholas C, Haider, Syed, Tutt, Andrew N J, Isacke, Clare M

“…Cerebrospinal fluid (CSF) cytology is the gold standard diagnostic test for breast cancer leptomeningeal metastasis (BCLM), but has impaired sensitivity, often…”
Get full text

Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer by Yeow, Zhong Y., Lambrus, Bramwell G., Marlow, Rebecca, Zhan, Kevin H., Durin, Mary-Anne, Evans, Lauren T., Scott, Phillip M., Phan, Thao, Park, Elizabeth, Ruiz, Lorena A., Moralli, Daniela, Knight, Eleanor G., Badder, Luned M., Novo, Daniela, Haider, Syed, Green, Catherine M., Tutt, Andrew N. J., Lord, Christopher J., Chapman, J. Ross, Holland, Andrew J.

“…Genomic instability is a hallmark of cancer, and has a central role in the initiation and development of breast cancer 1 , 2 . The success of poly-ADP ribose…”
Get full text

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant by Pettitt, Stephen J., Shao, Nan, Zatreanu, Diana, Frankum, Jessica, Bajrami, Ilirjana, Brough, Rachel, Krastev, Dragomir B., Roumeliotis, Theodoros I., Choudhary, Jyoti S., Lorenz, Sonja, Rust, Alistair, de Bono, Johann S., Yap, Timothy A., Tutt, Andrew N. J., Lord, Christopher J.

“…Although PARP inhibitors (PARPi) now form part of the standard-of-care for the treatment of homologous recombination defective cancers, de novo and acquired…”
Get full text

Targeting folate receptor alpha for cancer treatment by Cheung, Anthony, Bax, Heather J, Josephs, Debra H, Ilieva, Kristina M, Pellizzari, Giulia, Opzoomer, James, Bloomfield, Jacinta, Fittall, Matthew, Grigoriadis, Anita, Figini, Mariangela, Canevari, Silvana, Spicer, James F, Tutt, Andrew N, Karagiannis, Sophia N

“…Promising targeted treatments and immunotherapy strategies in oncology and advancements in our understanding of molecular pathways that underpin cancer…”
Get full text

Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply by Tutt, Andrew N J, Garber, Judy E, Geyer, Charles E

Get full text

Biologic markers determine both the risk and the timing of recurrence in breast cancer by Esserman, Laura J., Moore, Dan H., Tsing, Pamela J., Chu, Philip W., Yau, Christina, Ozanne, Elissa, Chung, Robert E., Tandon, Vickram J., Park, John W., Baehner, Frederick L., Kreps, Stig, Tutt, Andrew N. J., Gillett, Cheryl E., Benz, Christopher C.

“…Breast cancer has a long natural history. Established and emerging biologic markers address overall risk but not necessarily timing of recurrence. 346 adjuvant…”
Get full text